Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models.

MLA

Clappaert, Emile J., et al. “Flt3L Therapy Increases the Abundance of Treg-Promoting CCR7+ CDCs in Preclinical Cancer Models.” Frontiers in Immunology, Aug. 2023, pp. 01-11. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1166180.

APA

Clappaert, E. J., Kancheva, D., Brughmans, J., Debraekeleer, A., Bardet, P. M. R., Elkrim, Y., Lacroix, D., Živalj, M., Hamouda, A. E. I., Van Ginderachter, J. A., Deschoemaeker, S., & Laoui, D. (2023). Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models. Frontiers in Immunology, 01-11. https://doi.org/10.3389/fimmu.2023.1166180

Chicago

Clappaert, Emile J., Daliya Kancheva, Jan Brughmans, Ayla Debraekeleer, Pauline M. R. Bardet, Yvon Elkrim, Dagmar Lacroix, et al. 2023. “Flt3L Therapy Increases the Abundance of Treg-Promoting CCR7+ CDCs in Preclinical Cancer Models.” Frontiers in Immunology, August, 01-11. doi:10.3389/fimmu.2023.1166180.